Drug intelligence / Profile preview

Urolithin A

Development stage
Phase 2
Lead developer
Amazentis
Modality
Small Molecules
Administration
Oral
01

Overview

Urolithin A is a naturally occurring small molecule metabolite produced by the transformation of ellagitannins (found in foods like pomegranates and walnuts) by gut microbiota[6][5]. It is not present in food directly but results from microbial metabolism. Urolithin A has demonstrated antioxidant and anti-inflammatory properties and acts as an activator of mitophagy—the selective degradation of mitochondria via autophagy—thereby improving mitochondrial function and cellular health[1][2][4]. Mechanistically, it activates pathways such as PINK1/Parkin-mediated mitophagy and modulates signaling through Nrf2 and AMPK/PPARγ[2]. Preclinical studies suggest benefits for muscle health (promoting muscle protein synthesis), neuroprotection (potentially relevant to Alzheimer’s disease), metabolic diseases (type 2 diabetes mellitus), cardiovascular health, anti-aging effects, and cancer prevention[2][5][7]. Urolithin A is being developed primarily as a dietary supplement for healthy aging; clinical development status includes early-phase human trials with no major safety concerns reported over short durations[4].

Brand names
TimelineTimeline NutritionTimeline Longevity
Other names
urolithin a3,8-dihydroxyurolithin3,8-hydroxydibenzo-alpha-pyrone
02

Targets

PTGS2 (Prostaglandin-Endoperoxide Synthase 2)AMPK (Adenosine monophosphate–activated protein kinase)AHR (Aryl hydrocarbon receptor)NFE2L2 (Nuclear factor (erythroid-derived 2)-like 2)

Beyond the preview

Go deeper on Urolithin A.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Urolithin A.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call